Orally delivered single-domain antibodies against gastrointestinal pathogens

• World Health Organization

Global Action Plan on Antimicrobial Resistance.

World Health Organization, 2015

• Tagliabue A.
• Rappuoli R.

Changing priorities in vaccinology: antibiotic resistance moving to the top.

Front. Immunol. 2018; 9: 1068

• Niewiesk S.

Maternal antibodies: clinical significance, mechanism of interference with immune responses, and possible vaccination strategies.

Front. Immunol. 2014; 5: 446

• Slifka M.K.
• Amanna I.J.

Passive immunization.

Plotkins Vacc. 2018; 2018: 85-95

• Czosnykowska-Łukacka M.
• et al.

Changes in human milk immunoglobulin profile during prolonged lactation.

Front. Pediatr. 2020; 8: 428

• Laustsen A.H.
• et al.

Animal immunization, in vitro display technologies, and machine learning for antibody discovery.

Trends Biotechnol. 2021; 39: 1263-1273

• Rouet R.
• et al.

Fully human V_H single domains that rival the stability and cleft recognition of camelid antibodies.

J. Biol. Chem. 2015; 290: 11905-11917

• Muyldermans S.

Applications of nanobodies.

Annu. Rev. Anim. Biosci. 2021; 9: 401-421

• Muyldermans S.

Nanobodies: natural single-domain antibodies.

Annu. Rev. Biochem. 2013; 82: 775-797

• Steeland S.
• et al.

Nanobodies as therapeutics: big opportunities for small antibodies.

Drug Discov. Today. 2016; 21: 1076-1113

• Pérez J.M.
• et al.

Thermal unfolding of a llama antibody fragment: a two-state reversible process.

Biochemistry. 2001; 40: 74-83

• Lauwereys M.
• et al.

Potent enzyme inhibitors derived from dromedary heavy-chain antibodies.

EMBO J. 1998; 17: 3512-3520

• Dumoulin M.
• et al.

Single-domain antibody fragments with high conformational stability.

Protein Sci. Publ. Protein Soc. 2002; 11: 500-515

• Hussack G.
• et al.

Engineered single-domain antibodies with high protease resistance and thermal stability.

PLoS One. 2011; 6e28218

• Harmsen M.M.
• et al.

Escherichia coli F4 fimbriae specific llama single-domain antibody fragments effectively inhibit bacterial adhesion in vitro but poorly protect against diarrhoea.

Vet. Microbiol. 2005; 111: 89-98

• Moonens K.
• et al.

Nanobody mediated inhibition of attachment of F18 fimbriae expressing Escherichia coli.

PLoS One. 2014; 9e114691

• Harmsen M.M.
• et al.

Enhancement of toxin- and virus-neutralizing capacity of single-domain antibody fragments by N-glycosylation.

Appl. Microbiol. Biotechnol. 2009; 84: 1087-1094

• Virdi V.
• et al.

Orally fed seeds producing designer IgAs protect weaned piglets against enterotoxigenic Escherichia coli infection.

Proc. Natl. Acad. Sci. U. S. A. 2013; 110: 11809-11814

• Virdi V.
• et al.

Yeast-secreted, dried and food-admixed monomeric IgA prevents gastrointestinal infection in a piglet model.

Nat. Biotechnol. 2019; 37: 527-530

• Fiil B.K.
• et al.

Orally active bivalent V_HH construct prevents proliferation of F4⁺ enterotoxigenic Escherichia coli in weaned piglets.

iScience. 2022; 25104003

• Vanmarsenille C.
• et al.

Nanobodies targeting conserved epitopes on the major outer membrane protein of Campylobacter as potential tools for control of Campylobacter colonization.

Vet. Res. 2017; 48: 86

• Vanmarsenille C.
• et al.

In planta expression of nanobody-based designer chicken antibodies targeting Campylobacter.

PLoS One. 2018; 13e0204222

• Riazi A.
• et al.

Pentavalent single-domain antibodies reduce Campylobacter jejuni motility and colonization in chickens.

PLoS One. 2013; 8e83928

• Hussack G.
• et al.

Protease-resistant single-domain antibodies inhibit Campylobacter jejuni motility.

Protein Eng. Des. Sel. 2014; 27: 191-198

• Gonzales-Siles L.
• Sjöling Å.

The different ecological niches of enterotoxigenic Escherichia coli.

Environ. Microbiol. 2016; 18: 741-751

• Fairbrother J.M.
• et al.

Escherichia coli in postweaning diarrhea in pigs: an update on bacterial types, pathogenesis, and prevention strategies.

Anim. Health Res. Rev. 2005; 6: 17-39

• Luppi A.
• et al.

Prevalence of virulence factors in enterotoxigenic Escherichia coli isolated from pigs with post-weaning diarrhoea in Europe.

Porc. Health Manag. 2016; 2: 20

• Crottet P.
• Corthésy B.

Secretory component delays the conversion of secretory IgA into antigen-binding competent F(ab′)₂: a possible implication for mucosal defense.

J. Immunol. 1998; 161: 5445-5453

• Kaakoush N.O.
• et al.

Global epidemiology of Campylobacter infection.

Clin. Microbiol. Rev. 2015; 28: 687-720

Ghahroudi, M.A. et al. National Research Council of Canada. Anti-Campylobacter jejuni antibodies and uses therefor, US9926363B2

Abnousi, H. et al. Novobind Livestock Therapeutics Inc. Antibodies against aquaculture disease-causing agents and uses thereof, WO2020008254A1

Abnousi, H. et al. Novobind Livestock Therapeutics Inc. Antibodies against disease causing agents of poultry and uses thereof, WO2020234642A1

Laustsen, A.H. et al. Bactolife Aps. Pathogen binding proteins, US20220119505A1

• Arslan A.
• et al.

Bovine colostrum and its potential for human health and nutrition.

Front. Nutr. 2021; 8651721

• Kaplan M.
• et al.

Production of bovine colostrum for human consumption to improve health.

Front. Pharmacol. 2022; 12796824

• Playford R.J.
• Weiser M.J.

Bovine colostrum: its constituents and uses.

Nutrients. 2021; 13: 265

• Murray C.J.
• et al.

Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis.

Lancet. 2022; 399: 629-655

• World Health Organization

WHO preferred product characteristics for vaccines against enterotoxigenic Escherichia coli.

World Health Organization, 2021

• Amcheslavsky A.
• et al.

Anti-CfaE nanobodies provide broad cross-protection against major pathogenic enterotoxigenic Escherichia coli strains, with implications for vaccine design.

Sci. Rep. 2021; 11: 2751

• Ruano-Gallego D.
• et al.

A nanobody targeting the translocated intimin receptor inhibits the attachment of enterohemorrhagic E. coli to human colonic mucosa.

PLoS Pathog. 2019; 15e1008031

• Lu Z.
• et al.

Nanobody-based bispecific neutralizer for Shiga toxin-producing E. coli.

ACS Infect. Dis. 2022; 8: 321-329

• Vega C.G.
• et al.

Recombinant monovalent llama-derived antibody fragments (V_HH) to rotavirus VP6 protect neonatal gnotobiotic piglets against human rotavirus-induced diarrhea.

PLoS Pathog. 2013; 9e1003334

• Sarker S.A.
• et al.

Anti-rotavirus protein reduces stool output in infants with diarrhea: a randomized placebo-controlled trial.

Gastroenterology. 2013; 145: 740-748

• Maffey L.
• et al.

Anti-VP6 V_HH: an experimental treatment for rotavirus A-associated disease.

PLoS One. 2016; 11e0162351

• Unger M.
• et al.

Selection of nanobodies that block the enzymatic and cytotoxic activities of the binary Clostridium difficile toxin CDT.

Sci. Rep. 2015; 5: 7850

• Schmidt D.J.
• et al.

A tetraspecific V_HH-based neutralizing antibody modifies disease outcome in three animal models of Clostridium difficile infection.

Clin. Vaccine Immunol. 2016; 23: 774-784

• Yao G.
• et al.

A camelid single-domain antibody neutralizes botulinum neurotoxin A by blocking host receptor binding.

Sci. Rep. 2017; 7: 7438

• Ferrer-Miralles N.
• Villaverde A.

Bacterial cell factories for recombinant protein production; expanding the catalogue.

Microb. Cell Factories. 2013; 12: 113

• Wang M.
• et al.

Lactic acid bacteria as mucosal delivery vehicles: a realistic therapeutic option.

Appl. Microbiol. Biotechnol. 2016; 100: 5691-5701

• Cano-Garrido O.
• et al.

Lactic acid bacteria: reviewing the potential of a promising delivery live vector for biomedical purposes.

Microb. Cell Factories. 2015; 14: 137

• Günaydın G.
• et al.

Co-expression of anti-rotavirus proteins (llama V_HH antibody fragments) in Lactobacillus: development and functionality of vectors containing two expression cassettes in tandem.

PLoS One. 2014; 9e96409

• Gangaiah D.
• et al.

Recombinant Limosilactobacillus (Lactobacillus) delivering nanobodies against Clostridium perfringens NetB and alpha toxin confers potential protection from necrotic enteritis.

MicrobiologyOpen. 2022; 11e1270

• Andersen K.K.
• et al.

Neutralization of Clostridium difficile toxin B mediated by engineered Lactobacilli that produce single-domain antibodies.

Infect. Immun. 2016; 84: 395-406

• Álvarez B.
• et al.

An exopolysaccharide-deficient mutant of Lactobacillus rhamnosus GG efficiently displays a protective llama antibody fragment against rotavirus on its surface.

Appl. Environ. Microbiol. 2015; 81: 5784-5793

• Liu Y.
• Huang H.

Expression of single-domain antibody in different systems.

Appl. Microbiol. Biotechnol. 2018; 102: 539-551

• Zimmermann J.
• et al.

Antibody expressing pea seeds as fodder for prevention of gastrointestinal parasitic infections in chickens.

BMC Biotechnol. 2009; 9: 79

• Jester B.W.
• et al.

Development of spirulina for the manufacture and oral delivery of protein therapeutics.

Nat. Biotechnol. 2022; 40: 956-964

• Saberianfar R.
• et al.

Plant-produced chimeric V_HH–sIgA against enterohemorrhagic E. coli intimin shows cross-serotype inhibition of bacterial adhesion to epithelial cells.

Front. Plant Sci. 2019; 10: 270

• Shanmugaraj B.
• et al.

Plant molecular farming: a viable platform for recombinant biopharmaceutical production.

Plants. 2020; 9: 842

• De Meyer T.
• et al.

Comparison of V_HH-Fc antibody production in Arabidopsis thaliana, Nicotiana benthamiana and Pichia pastoris.

Plant Biotechnol. J. 2015; 13: 938-947

• Lessard P.A.
• et al.

Improved performance of Eimeria-infected chickens fed corn expressing a single-domain antibody against interleukin-10.

Nat. Food. 2020; 1: 119-126

• Tokuhara D.
• et al.

Rice-based oral antibody fragment prophylaxis and therapy against rotavirus infection.

J. Clin. Invest. 2013; 123: 3829-3838

• Sasou A.
• et al.

Development of antibody-fragment-producing rice for neutralization of human norovirus.

Front. Plant Sci. 2021; 12639953

• Burnett M.J.B.
• Burnett A.C.

Therapeutic recombinant protein production in plants: challenges and opportunities.

Plants People Planet. 2020; 2: 121-132

• Boune S.
• et al.

Principles of N-linked glycosylation variations of IgG-based therapeutics: pharmacokinetic and functional considerations.

Antibodies. 2020; 9: 22

• Mizukami M.
• et al.

Highly efficient production of V_HH antibody fragments in Brevibacillus choshinensis expression system.

Protein Expr. Purif. 2015; 105: 23-32

• Muyldermans S.

A guide to: generation and design of nanobodies.

FEBS J. 2021; 288: 2084-2102

• Ledsgaard L.
• et al.

Advances in antibody phage display technology.

Drug Discov. Today. 2022; 27: 2151-2169

• Pellis M.
• et al.

A bacterial-two-hybrid selection system for one-step isolation of intracellularly functional nanobodies.

Arch. Biochem. Biophys. 2012; 526: 114-123

• Kunz P.
• et al.

Nanobody stability engineering by employing the ΔTm shift; a comparison with apparent rate constants of heat-induced aggregation.

Protein Eng. Des. Sel. 2019; 32: 241-249

• Hagihara Y.
• et al.

Stabilization of an immunoglobulin fold domain by an engineered disulfide bond at the buried hydrophobic region.

J. Biol. Chem. 2007; 282: 36489-36495

• Saerens D.
• et al.

Disulfide bond introduction for general stabilization of immunoglobulin heavy-chain variable domains.

J. Mol. Biol. 2008; 377: 478-488

• Van de Wiele T.
• et al.

The simulator of the human intestinal microbial ecosystem (SHIME®).

in: Verhoeckx K. The Impact of Food Bioactives on Health: In Vitro and Ex Vivo Models. Springer, 2015: 305-317

• Minekus M.

The TNO gastro-intestinal model (TIM).

in: Verhoeckx K. The Impact of Food Bioactives on Health: In Vitro and Ex Vivo Models. Springer Open, 2015: 37-46

• Brodkorb A.
• et al.

INFOGEST static in vitro simulation of gastrointestinal food digestion.

Nat. Protoc. 2019; 14: 991-1014

• Hornbuckle W.E.
• et al.

Gastrointestinal function.

in: Kaneko J. Clinical Biochemistry of Domestic Animals. 6th edn. 2008: 413-457

• Baliga S.
• et al.

Salivary pH: a diagnostic biomarker.

J. Indian Soc. Periodontol. 2013; 17: 461-465

• Dressman J.B.
• et al.

Estimating drug solubility in the gastrointestinal tract.

Adv. Drug Deliv. Rev. 2007; 59: 591-602

• Dingus J.G.
• et al.

A general approach for stabilizing nanobodies for intracellular expression.

eLife. 2022; 11e68253

• Liu X.
• et al.

Preparation of a nanobody specific to dectin 1 and its anti-inflammatory effects on fungal keratitis.

Int. J. Nanomedicine. 2022; 17: 537-551

• Holmes A.H.
• et al.

Understanding the mechanisms and drivers of antimicrobial resistance.

Lancet. 2016; 387: 176-187

• Yang L.
• et al.

Distinct increase in antimicrobial resistance genes among Escherichia coli during 50 years of antimicrobial use in livestock production in China.

Nat. Food. 2022; 3: 197-205

• Wright G.D.

Molecular mechanisms of antibiotic resistance.

Chem. Commun. 2011; 47: 4055-4061

• Uchil R.R.
• et al.

Strategies to combat antimicrobial resistance.

J. Clin. Diagn. Res. 2014; 8: ME01-ME04

• Diard M.
• Hardt W.-D.

Evolution of bacterial virulence.

FEMS Microbiol. Rev. 2017; 41: 679-697

• Kitamoto S.
• et al.

Regulation of virulence: the rise and fall of gastrointestinal pathogens.

J. Gastroenterol. 2016; 51: 195-205

• Pakbin B.
• et al.

Virulence factors of enteric pathogenic Escherichia coli: a review.

Int. J. Mol. Sci. 2021; 22: 9922

• Kaper J.B.
• et al.

Pathogenic Escherichia coli.

Nat. Rev. Microbiol. 2004; 2: 123-140

• Rasko D.A.
• Sperandio V.

Anti-virulence strategies to combat bacteria-mediated disease.

Nat. Rev. Drug Discov. 2010; 9: 117-128